News

Lynch syndrome awareness day

Lynch syndrome. Even though it is the most common hereditary cancer syndrome in the world, it is mostly unknown. Lynch syndrome prevalence is currently estimated at 1 in 279 globally[1], meaning that in Europe alone

... read more
22.3.2020

Announcement – CSO Appointment

We are excited to announce that Minttu Kansikas has been appointed as Chief Scientific Officer to lead the research efforts and laboratory functions. Congratulations! Minttu is a co-inventor and one of the leading scientists behind

... read more
19.12.2019

Welcome to our updated Website

Welcome! We have updated our website and hope you enjoy the new structure and features! This new section being one of them, and the twitter feed, being another. And there are many more to come!

... read more
18.12.2019

LS CancerDiag joins InvestHorizon Accelerator

LS CancerDiag joins the InvestHorizon Accelerator, we are delighted to have been accepted to the programme! InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding. The selected deep tech companies

... read more
18.10.2019

LS CancerDiagFollow

We detect #LynchSyndrome and predict cancer with our novel #DiagMMR test, enabling personalized and preventive care for affected families. #MissionCancer

Avatar
Retweet on TwitterLS CancerDiag Retweeted
AvatarTerkko Health Hub@terkko·
5 Nov

Proud to see our current member @lscancerdiag and a bunch of our alumni startups and corporate partners featured in the digital booklet showcasing world-class diagnostic innovations from Finland!🙌 https://www.businessfinland.fi/en/whats-new/news/2021/world-class-diagnostic-innovations-from-finland

@BusinessFinland

Reply on Twitter 1456550696082411522Retweet on Twitter 14565506960824115221Like on Twitter 14565506960824115221Twitter 1456550696082411522
Retweet on TwitterLS CancerDiag Retweeted
AvatarStartup100 Finland@Startup100_fi·
6 Aug

Trending #startups in August:
@BCasterltd, iFarm, @CanitApp, @Made_of_Sundays, @lscancerdiag, @Pikasiirto, @immersal_ar, @MrAutofire, @LogmoreLtd, @combinostics.

Check out the full list at http://startup100.net 🔥

Reply on Twitter 1423583333968236547Retweet on Twitter 14235833339682365473Like on Twitter 142358333396823654711Twitter 1423583333968236547
Retweet on TwitterLS CancerDiag Retweeted
AvatarULISES@ulises_eu·
17 Jun

🩺Did you know that 40% of cancer cases are preventable?

📝@EU_Commission's #BeatingCancerPlan aims to protect people from avoidable cancers, improve access to screening & early diagnosis

👉https://ec.europa.eu/info/strategy/priorities-2019-2024/promoting-our-european-way-life/european-health-union/cancer-plan-europe_en #EUCancerPlan #MissionCancer

Reply on Twitter 1405461900977184778Retweet on Twitter 14054619009771847782Like on Twitter 14054619009771847785Twitter 1405461900977184778
Retweet on TwitterLS CancerDiag Retweeted
AvatarEIT Health Scandinavia@EITHealthScand·
15 Jun

Congratulations to our Six Scandinavian start-ups ready for EIT Health Catapult Semifinals @eithealth @cardiolyse @lscancerdiag @KamuHealth @Finnadvance https://www.mynewsdesk.com/se/eit-health-scandinavia/pressreleases/six-scandinavian-start-ups-ready-for-eit-health-catapult-semifinals-3109203

Reply on Twitter 1404792464586772485Retweet on Twitter 14047924645867724851Like on Twitter 14047924645867724856Twitter 1404792464586772485
Load More...

Contact Us

  • For general inquiries:
    contact (at) lscancerdiag.com
  • For technical support:
    +358 40 6602622
  • LS CancerDiag Ltd
    c/o Terkko Health Hub
    Haartmaninkatu 4, Building 14
    00290 Helsinki
    Finland

Privacy Policy

This document informs you about privacy issues such as the collection, storage, use and disclosure of personal information received from users of this Website, and of personal information received in the course of the provided services.

Contact

If you have any questions about this Privacy Policy, your data, or if you would like to exercise one of your data protection rights, please do not hesitate to contact our data protection officer at:

LS CancerDiag Ltd
Business ID 2558287-9
c/o Terkko Health Hub
Haartmaninkatu 4, Building 14
00290 Helsinki
Finland

Email: privacy@lscancerdiag.com

Data we may collect about you

If you are a website visitor, we may collect your name, email, and cookies.

If you are a patient, we may collect your name, date of birth, gender, ethnicity, nationality, identifiable genetic information, health-related information from your physician, specimen identification number and equivalent identifiers, family history and relationships.

If you are a customer, marketing contact, or job applicant, we may collect your name, contact details and relevant professional data.

If you are an employee or corporate-related member of LS CancerDiag Ltd, this privacy statement does not apply to you. You may contact LS CancerDiag Ltd for the relevant privacy notice.

How we receive your data

If you are a website visitor, customer, marketing contact, or job applicant, your data is collected by us with your consent.

If you are a patient, your data is collected by your healthcare facility or intermediary lab testing facility and send to us for diagnostic testing.

How we use your data

We look at the trend of our website visitors to understand how we can improve our online communication about our services. Some data may be visible, such as your cookies, and from where you access our website. Other information may not be visible to us.

We provide our services, such as diagnostic testing and analysis, to our customers, and keep them informed about our company updates.

We are building our network with marketing contacts to make sure our company updates and achievements are spread within the community.

Data from job applicants is kept with specific consent for future career opportunities, or deleted after completion of the interview process.

Data from patients is used for diagnostic testing, to provide the patient’s physician health-related information about the patient and its family. If the patient has provided informed consent to its healthcare facility, we may also use the patient data for further research to improve our internal diagnostic testing services, or acquire a deeper academic understanding about the specifics of the Lynch syndrome.

How we protect your data

We have implemented several technical and organizational measures to protect the identity of any of our data subjects.

We use only secured electronic tools, which acquired prior approval by our data protection officer, and which are subject to regular review and updates. We do not make use of automatic decision-making tools.

Within our organization, only authorized personnel are assigned to process specific types of data originating from patients, customers and marketing contacts, and employees and job applicants. All personnel, new or onboarding staff, consultants, external or technical advisers are only allowed to process data that is specifically required to fulfill their work-related purpose, and only when they have obtained prior authorization.

We are processing patient-related information under pseudonymized references to make sure no identifying information is revealed when used for diagnostic testing and, in those instances, where the results are used for further internal research purposes.

 

Regularly we audit, review, update and communicate our data protection policy documentation, risk assessment, breach policy, IT systems and policies, storage and retention documentation under guidance of our data protection officer together with the entire team, and we record the results in our data protection registry of records.

Do we share your data

We only share your data with sub-processors we have carefully vetted and are authorized by our data protection officer, to assist us in providing our diagnostic services, such as external electronic tools to store your data in protected clouds, or couriers to send your samples to the healthcare facility.

Unless explicitly authorized to do so by a legal obligation, we do not share your personal data with any other third parties.

Do we transfer your data

LS CancerDiag Ltd is based in Finland and does not transfer data from our website visitor, customer, marketing contact, job applicants or patient data outside the European Economic Area, unless your data is stored in Cloud services outside the European Economic Area. In those instances, we have ensured carefully the legal contractual requirements to make use of these services to fully protect the identity of the data subjects.

If LS CancerDiag Ltd has received patient data from a healthcare or intermediary lab testing facility within the European Economic Area, we will not transfer your data physically outside the Union.

In the event we have received patient data from a healthcare or intermediary lab testing facility outside the European Economic Area, we will transfer your data physically outside the Union, carefully and in compliance with the legal requirements for international transfers.

How long do we store your data

We retain data regarding our website visitors, that is identifiable in some nature, for maximum of one year. Website data, which is anonymous, is not subject to data protection laws and kept indefinitely.

Data regarding customers and marketing contacts, are kept for a duration of two to five years, depending on the nature of the business relationship. Each year this data will be reviewed and established if it is necessary to retain the data.

Data regarding job applicants will be kept throughout the interview process and deleted within sixty days after conclusion. In the event the job applicant wishes to remain in our database for future job opportunities, we will keep the data for a duration of maximum one year.

Health-related data from patients will be kept internally within our company for not longer than ten years.

How can I exercise my data protection rights?

As a website visitor, customer or marketing contact or job applicant, you have at all times the right to:

  • access your data and request copies of all processing activities concerning your data;
  • rectify information concerning any data about you that you believe is inaccurate;
  • request to be forgotten, to which we can comply under certain conditions: such as when we are not following a legal obligation from a National Authority, or reasons for public interest or public health;
  • request to restrict or object to processing, to which we can comply under certain conditions, such as when we are not following a legal obligation from a National Authority, or reasons for public interest or public health;
  • request a structured, commonly used and machine-readable format to transfer the data to another controller or directly to you (portability).

 

As a patient, you have in principle the same rights as stated above. However, in some instances we may not be able to comply because we are not your data controller. In those instances, may you contact us, we will refer to your healthcare facility and we will assist your data controller to the best of our abilities.

Complaints

Please feel free to consult us about your data protection rights, or any privacy matter related to you. Should you LS CancerDiag Ltd has not addressed your concerns in a satisfying manner, or you wish to report a complaint, you may contact the Data Protection Authority in Finland or in your country of residence.

Updates

This policy was last updated Ferburary 2021. LS CancerDiag Ltd will keep this privacy policy continuously under review and reserves the right to modify this document. LS CancerDiag Ltd advises you to regularly to consult this document for the latest updates.

Privacy Policy

Navigate

Follow us

Linkedin Twitter Facebook Youtube
Follow LS CancerDiag on F6S

Send message

Newsletter Subscription

X-Europe
bf_logo_blue_rgb
image (2)
ProHEALTH_accelerator_colour
EIT Health accelerated by - Web
StartupHealth
Previous
Next
X-Europe